FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3204109254> ?p ?o ?g. }

• W3204109254 endingPage "S952" @default.
• W3204109254 startingPage "S951" @default.
• W3204109254 abstract "Amivantamab (ami), an epidermal growth factor receptor (EGFR)-MET bispecific antibody, has demonstrated efficacy in EGFR mutant non-small cell lung cancer (NSCLC) that progressed on osimertinib (osi), both as monotherapy and in combination with lazertinib (laz), a 3rd-generation tyrosine kinase inhibitor. Clinical outcomes of patients (pts) treated with ami monotherapy (mono) and ami in combination with laz (combo) are presented here. CHRYSALIS is an ongoing study of ami in pts with advanced EGFR mutant NSCLC (NCT02609776). Pts who progressed on osi were pooled to form the mono group, a majority of whom were preselected for C797S/other resistance mutations or MET amplification. The combo group comprised unselected pts who had progressed on osi but were chemotherapy-naïve. Response was assessed by the investigator per RECIST v1.1. As of 19 Apr 2021, 121 pts in the mono group (85% with EGFR/MET-based resistance) and 45 in the combo group (38% with EGFR/MET-based resistance) were efficacy-evaluable, with median follow-up of 6.9 and 11.1 months, respectively. Antitumor activity was observed in the mono group, with 33 achieving partial response (PR) as best response, of which 23 were confirmed, for an overall response rate (ORR) of 19% (95% CI, 12–27). In the combo group, 1 complete response and 15 PRs were observed, all of which confirmed, for an ORR of 36% (95% CI, 22–51). Median duration of response was 5.9 months with mono, 9.6 months with combo (Table). The safety profile for both mono and combo was consistent with previously-reported safety. No new safety signals were identified. Antitumor activity of ami + laz in the post-osi setting appears favorable even without molecular selection post osimertinib failure, supporting that simultaneous targeting of the extracellular and catalytic domains of EGFR provides additive benefits.Table: 1192MOEfficacy of amivantamab monotherapy and in combination with lazertinib among efficacy-evaluablea patientsEfficacyMonotherapy (n=121)Combination (n=45)ORR (95% CI)19% (12–27)36% (22–51)CBR (95% CI)48% (39–57)64% (49–78)mDOR, month (95% CI)5.9 (4.2–12.6)9.6 (5.3–NR)aPatients who had at least 2 post-baseline disease assessment or discontinued before the second assessment. CBR, clinical benefit rate (complete response, partial response, or stable disease of at least 11 weeks); mDOR, median duration of response; ORR, overall response rate; NR, not reached Open table in a new tab" @default.
• W3204109254 created "2021-10-11" @default.
• W3204109254 creator A5001400866 @default.
• W3204109254 creator A5006299989 @default.
• W3204109254 creator A5006869052 @default.
• W3204109254 creator A5007163286 @default.
• W3204109254 creator A5017876333 @default.
• W3204109254 creator A5034407359 @default.
• W3204109254 creator A5042316451 @default.
• W3204109254 creator A5048354121 @default.
• W3204109254 creator A5048979897 @default.
• W3204109254 creator A5054055121 @default.
• W3204109254 creator A5058623156 @default.
• W3204109254 creator A5066347620 @default.
• W3204109254 creator A5073321006 @default.
• W3204109254 creator A5073795960 @default.
• W3204109254 creator A5077503594 @default.
• W3204109254 creator A5078816311 @default.
• W3204109254 creator A5082384956 @default.
• W3204109254 creator A5083647108 @default.
• W3204109254 creator A5085631899 @default.
• W3204109254 creator A5090324173 @default.
• W3204109254 date "2021-09-01" @default.
• W3204109254 modified "2023-10-18" @default.
• W3204109254 title "1192MO Amivantamab monotherapy and in combination with lazertinib in post-osimertinib EGFR-mutant NSCLC: Analysis from the CHRYSALIS study" @default.
• W3204109254 doi "https://doi.org/10.1016/j.annonc.2021.08.1797" @default.
• W3204109254 hasPublicationYear "2021" @default.
• W3204109254 type Work @default.
• W3204109254 sameAs 3204109254 @default.
• W3204109254 citedByCount "13" @default.
• W3204109254 countsByYear W32041092542022 @default.
• W3204109254 countsByYear W32041092542023 @default.
• W3204109254 crossrefType "journal-article" @default.
• W3204109254 hasAuthorship W3204109254A5001400866 @default.
• W3204109254 hasAuthorship W3204109254A5006299989 @default.
• W3204109254 hasAuthorship W3204109254A5006869052 @default.
• W3204109254 hasAuthorship W3204109254A5007163286 @default.
• W3204109254 hasAuthorship W3204109254A5017876333 @default.
• W3204109254 hasAuthorship W3204109254A5034407359 @default.
• W3204109254 hasAuthorship W3204109254A5042316451 @default.
• W3204109254 hasAuthorship W3204109254A5048354121 @default.
• W3204109254 hasAuthorship W3204109254A5048979897 @default.
• W3204109254 hasAuthorship W3204109254A5054055121 @default.
• W3204109254 hasAuthorship W3204109254A5058623156 @default.
• W3204109254 hasAuthorship W3204109254A5066347620 @default.
• W3204109254 hasAuthorship W3204109254A5073321006 @default.
• W3204109254 hasAuthorship W3204109254A5073795960 @default.
• W3204109254 hasAuthorship W3204109254A5077503594 @default.
• W3204109254 hasAuthorship W3204109254A5078816311 @default.
• W3204109254 hasAuthorship W3204109254A5082384956 @default.
• W3204109254 hasAuthorship W3204109254A5083647108 @default.
• W3204109254 hasAuthorship W3204109254A5085631899 @default.
• W3204109254 hasAuthorship W3204109254A5090324173 @default.
• W3204109254 hasBestOaLocation W32041092541 @default.
• W3204109254 hasConcept C104317684 @default.
• W3204109254 hasConcept C121608353 @default.
• W3204109254 hasConcept C126322002 @default.
• W3204109254 hasConcept C143065580 @default.
• W3204109254 hasConcept C143998085 @default.
• W3204109254 hasConcept C2777626846 @default.
• W3204109254 hasConcept C2778087573 @default.
• W3204109254 hasConcept C2779438470 @default.
• W3204109254 hasConcept C502942594 @default.
• W3204109254 hasConcept C54355233 @default.
• W3204109254 hasConcept C71924100 @default.
• W3204109254 hasConcept C86803240 @default.
• W3204109254 hasConceptScore W3204109254C104317684 @default.
• W3204109254 hasConceptScore W3204109254C121608353 @default.
• W3204109254 hasConceptScore W3204109254C126322002 @default.
• W3204109254 hasConceptScore W3204109254C143065580 @default.
• W3204109254 hasConceptScore W3204109254C143998085 @default.
• W3204109254 hasConceptScore W3204109254C2777626846 @default.
• W3204109254 hasConceptScore W3204109254C2778087573 @default.
• W3204109254 hasConceptScore W3204109254C2779438470 @default.
• W3204109254 hasConceptScore W3204109254C502942594 @default.
• W3204109254 hasConceptScore W3204109254C54355233 @default.
• W3204109254 hasConceptScore W3204109254C71924100 @default.
• W3204109254 hasConceptScore W3204109254C86803240 @default.
• W3204109254 hasLocation W32041092541 @default.
• W3204109254 hasOpenAccess W3204109254 @default.
• W3204109254 hasPrimaryLocation W32041092541 @default.
• W3204109254 hasRelatedWork W2593927093 @default.
• W3204109254 hasRelatedWork W2765285169 @default.
• W3204109254 hasRelatedWork W3135851905 @default.
• W3204109254 hasRelatedWork W3137075329 @default.
• W3204109254 hasRelatedWork W3172491611 @default.
• W3204109254 hasRelatedWork W3197306284 @default.
• W3204109254 hasRelatedWork W3202081120 @default.
• W3204109254 hasRelatedWork W4295168981 @default.
• W3204109254 hasRelatedWork W4318323499 @default.
• W3204109254 hasRelatedWork W4385331418 @default.
• W3204109254 hasVolume "32" @default.
• W3204109254 isParatext "false" @default.
• W3204109254 isRetracted "false" @default.
• W3204109254 magId "3204109254" @default.
• W3204109254 workType "article" @default.